HUTCHMED (China) Limited will announce its 2025 final results on March 5, 2026, with webcast presentations in English and Chinese. The company has published Phase III SACHI trial results confirming MET inhibition efficacy in advanced NSCLC patients and announced positive Phase III results for sovleplenib in treating warm antibody autoimmune hemolytic anemia.

The SACHI Phase III trial demonstrated that the combination of savolitinib (ORPATHYS®) and osimertinib (TAGRISSO®) significantly improved progression-free survival (8.2 vs 4.5 months) compared to chemotherapy in patients with EGFR-mutated NSCLC with MET amplification after EGFR-TKI progression. The combination was approved in China in June 2025 and results were published in The Lancet.

HUTCHMED announced positive Phase III topline results for sovleplenib in treating warm antibody autoimmune hemolytic anemia (wAIHA) in China, meeting its primary endpoint of durable hemoglobin response rate. The company plans to submit a New Drug Application to China's NMPA in the first half of 2026. Phase II results showed a 43.8% response rate versus 0% for placebo in the first 8 weeks.

HUTCHMED has initiated the Phase III portion of a Phase II/III trial evaluating the combination of surufatinib, camrelizumab, nab-paclitaxel, and gemcitabine for treatment-naïve metastatic pancreatic ductal adenocarcinoma in China. Phase II results showed the combination achieved a median PFS of 7.20 months versus 5.52 months for chemotherapy alone, representing a 50.1% reduction in progression or death risk, with a favorable overall survival trend.

HUTCHMED announced that its New Drug Application (NDA) for fanregratinib (HMPL-453) has been accepted with priority review status by China's NMPA for treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The NDA is supported by a Phase II registration trial in China that met its primary endpoint of objective response rate, with positive secondary endpoints including progression-free survival, disease control rate, duration of response, and overall survival.

Over 30 pharmaceutical companies are developing BTK inhibitors targeting B-cell cancers, autoimmune disorders, and neurological conditions, with promising pipeline drugs in various clinical trial stages.

HUTCHMED launched a global Phase I/IIa clinical trial for HMPL-A251, a novel antibody-targeted therapy conjugate (ATTC) designed to treat HER2-expressing solid tumors with potentially improved safety and efficacy.

Over 100 pharmaceutical companies are actively developing 150+ pipeline drugs for Acute Myeloid Leukemia (AML), with approximately 10 drugs in late-stage development and 50+ in mid and early stages, focusing on targeted therapies and personalized treatment approaches.

HUTCHMED will present clinical data on multiple compounds at two major medical conferences, including studies on fruquintinib, HMPL-A83, savolitinib, surufatinib, and sovleplenib across various cancer and medical conditions.

HUTCHMED introduced its Antibody-Targeted Therapy Conjugate (ATTC) platform, focusing on a novel approach to cancer treatment using targeted therapies with dual mechanisms of action. The lead candidate HMPL-A251 demonstrates promising preclinical efficacy in targeting HER2-positive tumors with improved safety profiles.

Deutsche Bank will host a virtual investor conference on November 4, 2025, featuring live webcasts from international companies with American Depositary Receipt (ADR) programs, representing firms from multiple countries including China, Australia, and Germany.

Dr. Weiguo Su is taking a medical leave of absence as CEO, with Johnny Cheng appointed as Acting CEO. The board expressed full support for Dr. Su and confidence in Mr. Cheng's leadership during this interim period.